新型喹诺酮类药物对棒状杆菌的体外活性比较
Comparative in vitro activities of new quinolones against coryneform bacteria.
作者信息
Martínez-Martínez L, Suárez A I, Ortega M C, Perea E J
机构信息
Department of Microbiology, University Hospital Virgen Macarena, University of Seville, Spain.
出版信息
Antimicrob Agents Chemother. 1994 Jun;38(6):1439-41. doi: 10.1128/AAC.38.6.1439.
Abstract
The in vitro activities of eight quinolones against 115 coryneform bacteria (20 Corynebacterium jeikeium, 15 Corynebacterium minutissimum, 15 Corynebacterium striatum, 25 Corynebacterium urealyticum, 10 Corynebacterium xerosis, 10 Corynebacterium group ANF-1, 10 Corynebacterium group 12, and 10 Listeria monocytogenes) were determined. The MICs of ciprofloxacin, ofloxacin, and sparfloxacin for 90% of C. jeikeium, C. urealyticum, and C. xerosis isolates tested were > 16 micrograms/ml. Those of BAY Y 3118 and clinafloxacin against these species were 0.5 and 1 to 2 micrograms/ml, respectively. The MICs for 90% of all 115 strains tested were 0.5 microgram/ml for BAY Y 3118, 1 microgram/ml for clinafloxacin, 2 micrograms/ml for E-5068, 4 micrograms/ml for E-5065, and > 16 micrograms/ml for ciprofloxacin, ofloxacin, sparfloxacin, and E-4868.
摘要
测定了8种喹诺酮类药物对115株棒状杆菌（20株杰氏棒状杆菌、15株极小棒状杆菌、15株纹带棒状杆菌、25株解脲棒状杆菌、10株干燥棒状杆菌、10株ANF-1棒状杆菌群、10株12群棒状杆菌和10株单核细胞增生李斯特菌）的体外活性。环丙沙星、氧氟沙星和司帕沙星对90%受试的杰氏棒状杆菌、解脲棒状杆菌和干燥棒状杆菌分离株的最低抑菌浓度（MIC）>16微克/毫升。BAY Y 3118和克林沙星对这些菌种的MIC分别为0.5和1至2微克/毫升。对于所有115株受试菌株，90%的菌株对BAY Y 3118的MIC为0.5微克/毫升，对克林沙星为1微克/毫升，对E-5068为2微克/毫升，对E-5065为4微克/毫升，对环丙沙星、氧氟沙星、司帕沙星和E-4868则>16微克/毫升。
相似文献
1
Comparative in vitro activities of new quinolones against coryneform bacteria.新型喹诺酮类药物对棒状杆菌的体外活性比较
Antimicrob Agents Chemother. 1994 Jun;38(6):1439-41. doi: 10.1128/AAC.38.6.1439.
2
In-vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes.左氧氟沙星、氧氟沙星和D-氧氟沙星对棒状杆菌和单核细胞增生李斯特菌的体外活性。
J Antimicrob Chemother. 1999 Jun;43 Suppl C:27-32. doi: 10.1093/jac/43.suppl_3.27.
3
Comparative activities of eight quinolones against members of the Bacteroides fragilis group.八种喹诺酮类药物对脆弱拟杆菌群成员的比较活性
Antimicrob Agents Chemother. 1994 Jun;38(6):1442-5. doi: 10.1128/AAC.38.6.1442.
4
[Activity of new quinolones against clinical isolates of Corynebacterium species].[新型喹诺酮类药物对棒状杆菌属临床分离株的活性]
Rev Esp Quimioter. 2000 Sep;13(3):267-70.
5
Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.123株嗜麦芽窄食单胞菌对克林沙星、PD 131628、PD 138312、PD 140248、环丙沙星和氧氟沙星的敏感性。
Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. doi: 10.1128/AAC.38.2.369.
6
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.环丙沙星、氧氟沙星、司帕沙星、替马沙星、CI-960、CI-990和WIN 57273对厌氧菌的比较活性。
Antimicrob Agents Chemother. 1992 May;36(5):1158-62. doi: 10.1128/AAC.36.5.1158.
7
Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.三种研究性氟喹诺酮类药物（BAY y 3118、DU-6859a和克林沙星）对环丙沙星和氧氟沙星敏感性降低的淋病奈瑟菌分离株的活性。
Antimicrob Agents Chemother. 1995 Jul;39(7):1606-8. doi: 10.1128/AAC.39.7.1606.
8
Activities of gemifloxacin and five other antimicrobial agents against Listeria monocytogenes and coryneform bacteria isolated from clinical samples.吉米沙星及其他五种抗菌药物对从临床样本中分离出的单核细胞增生李斯特菌和棒状杆菌的活性。
Antimicrob Agents Chemother. 2001 Aug;45(8):2390-2. doi: 10.1128/AAC.45.8.2390-2392.2001.
9
Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.使用环丙沙星耐药菌预测菌组对克林沙星与环丙沙星、氟罗沙星、氧氟沙星和司帕沙星进行交叉耐药性分析。
J Antimicrob Chemother. 1995 Aug;36(2):431-4. doi: 10.1093/jac/36.2.431.
10
Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.人型支原体和解脲脲原体对两种新型喹诺酮类药物（司帕沙星和WIN 57273）的敏感性
Antimicrob Agents Chemother. 1991 Jul;35(7):1515-6. doi: 10.1128/AAC.35.7.1515.
引用本文的文献
1
Encrusted Uropathy: A Comprehensive Overview-To the Bottom of the Crust.结痂性尿道病：全面概述——深入探究痂皮之下
Front Med (Lausanne). 2021 Jan 21;7:609024. doi: 10.3389/fmed.2020.609024. eCollection 2020.
2
Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest.ABT-773对产单核细胞李斯特菌及临床相关棒状杆菌的活性。
Antimicrob Agents Chemother. 2003 Apr;47(4):1403-6. doi: 10.1128/AAC.47.4.1403-1406.2003.
3
Activities of gemifloxacin and five other antimicrobial agents against Listeria monocytogenes and coryneform bacteria isolated from clinical samples.吉米沙星及其他五种抗菌药物对从临床样本中分离出的单核细胞增生李斯特菌和棒状杆菌的活性。
Antimicrob Agents Chemother. 2001 Aug;45(8):2390-2. doi: 10.1128/AAC.45.8.2390-2392.2001.
4
In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials.需氧及兼性无芽孢革兰氏阳性杆菌对HMR 3647（RU 66647）及其他14种抗菌药物的体外敏感性
Antimicrob Agents Chemother. 1998 May;42(5):1028-33. doi: 10.1128/AAC.42.5.1028.
5
Clinical microbiology of coryneform bacteria.棒状杆菌的临床微生物学
Clin Microbiol Rev. 1997 Jan;10(1):125-59. doi: 10.1128/CMR.10.1.125.
6
Antimicrobial susceptibility pattern of Corynebacterium striatum.纹带棒状杆菌的抗菌药敏模式
Antimicrob Agents Chemother. 1996 Nov;40(11):2671-2. doi: 10.1128/AAC.40.11.2671.
7
In vitro activity of fluoroquinolones against gram-positive bacteria.氟喹诺酮类药物对革兰氏阳性菌的体外活性。
Drugs. 1995;49 Suppl 2:48-57. doi: 10.2165/00003495-199500492-00009.
8
Comparison of E-test with broth microdilution and disk diffusion for susceptibility testing of coryneform bacteria.E试验与肉汤微量稀释法及纸片扩散法用于棒状杆菌药敏试验的比较。
J Clin Microbiol. 1995 May;33(5):1318-21. doi: 10.1128/jcm.33.5.1318-1321.1995.
9
Phenotypic characteristics of 31 strains of Corynebacterium striatum isolated from clinical samples.从临床样本中分离出的31株纹带棒状杆菌的表型特征。
J Clin Microbiol. 1995 Sep;33(9):2458-61. doi: 10.1128/jcm.33.9.2458-2461.1995.
本文引用的文献
1
In vitro activity of ciprofloxacin against group JK corynebacteria.环丙沙星对JK群棒状杆菌的体外活性。
Eur J Clin Microbiol. 1984 Aug;3(4):375. doi: 10.1007/BF01977504.
2
Susceptibility of urinary isolates of Corynebacterium group D2 to fifteen antimicrobials and acetohydroxamic acid.D2群棒状杆菌尿液分离株对十五种抗菌药物及乙酰氧肟酸的敏感性
J Antimicrob Chemother. 1987 Sep;20(3):349-55. doi: 10.1093/jac/20.3.349.
3
The in-vitro activity of PD127,391, a new quinolone.新型喹诺酮类药物PD127,391的体外活性
J Antimicrob Chemother. 1988 Aug;22(2):135-41. doi: 10.1093/jac/22.2.135.
4
Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative.新型氟化4-喹诺酮衍生物PD 127,391的体外活性比较
Antimicrob Agents Chemother. 1988 Aug;32(8):1278-81. doi: 10.1128/AAC.32.8.1278.
5
In vitro activity of PD 127,391, an enhanced-spectrum quinolone.广谱喹诺酮类药物PD 127,391的体外活性
Antimicrob Agents Chemother. 1988 Aug;32(8):1251-6. doi: 10.1128/AAC.32.8.1251.
6
Fluoroquinolone antimicrobial agents.氟喹诺酮类抗菌剂。
Clin Microbiol Rev. 1989 Oct;2(4):378-424. doi: 10.1128/CMR.2.4.378.
7
Listeriosis.李斯特菌病
JAMA. 1989 Mar 3;261(9):1313-20.
8
Coryneform bacteria in infectious diseases: clinical and laboratory aspects.感染性疾病中的棒状杆菌：临床与实验室方面
Clin Microbiol Rev. 1990 Jul;3(3):227-46. doi: 10.1128/CMR.3.3.227.
9
In vitro susceptibility of Corynebacterium group D2 and Corynebacterium jeikeium to twelve antibiotics.D2群棒状杆菌和杰氏棒状杆菌对十二种抗生素的体外敏感性
Eur J Clin Microbiol Infect Dis. 1990 Dec;9(12):892-5. doi: 10.1007/BF01967505.
10
In vitro activity of 79 antimicrobial agents against Corynebacterium group D2.79种抗菌剂对D2群棒状杆菌的体外活性
Antimicrob Agents Chemother. 1991 Oct;35(10):2140-3. doi: 10.1128/AAC.35.10.2140.
Zotero 插件